CN101095928A - Chinese traditional medicine composition for treating nephritis - Google Patents
Chinese traditional medicine composition for treating nephritis Download PDFInfo
- Publication number
- CN101095928A CN101095928A CNA2007100121754A CN200710012175A CN101095928A CN 101095928 A CN101095928 A CN 101095928A CN A2007100121754 A CNA2007100121754 A CN A2007100121754A CN 200710012175 A CN200710012175 A CN 200710012175A CN 101095928 A CN101095928 A CN 101095928A
- Authority
- CN
- China
- Prior art keywords
- cortex
- nephritis
- weight
- treatment
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal combination for treating nephritis, which is prepared from the following raw materials (by weight portions)through the steps of water extracting, concentrating and drying: phellodendron bark 1-5, cortex acanthopanacis 1-5, mulberry bark 2-6, ginger peel 2-6, poria peel 2-6, areca catecha 1-5 and dried orange peel 2-6.
Description
Technical field
The present invention relates to a kind of Chinese medicine product, particularly a kind of Chinese medicine composition that is used for the treatment of nephritis is the first-selected curative of acute nephritis, for the nephrotic syndrome better curative effect is arranged also.
Background technology
Nephritis is a kind of commonly encountered diseases frequently-occurring disease, and sickness rate height, the patient is wide, from the child, teenager all has the possibility of suffering from nephritis to person in middle and old age, become chronic nephritis as untimely treatment meeting by acute nephritis, even also can develop into the nephrotic syndrome, uremia and renal failure etc. become difficult and complicated illness, not only the healthy of people in serious harm, and finally go back threat to life, although yet up to the present still imperfectly understand for the pathogeny of nephritis, it is generally acknowledged that acute nephritis is a kind of because to infect the both sides kidney diffusivity glomerule infringement that the back allergy causes be main acute illness.It falls ill anxious, and a series of clinical manifestations such as hematuria, albuminuria, cylinderuria, edema, oliguria and hypertension appear in 1-3 week after infection; Chronic nephritis is that a kind of albuminuria, hematuria, edema, hypertension of growing the course of disease that various primary glomerulopathies cause is the disease of clinical manifestation.At present acute and chronic nephritis also there is not the specific treatment method, each medical institutions mainly was a Therapeutic Method of eliminating and alleviate acute symptom in the past, intramuscular injection every day 800,000 unit penicillins normally, use tetracycline or erythromycin 7-10 days instead as allergy sufferers, go back symptomatic treatment with plug diuresis of two hydrogen urine and reserpine blood pressure lowering treatment.Therapeutic modality in the past is because the treatment route is very unreasonable and no specially good effect symptomatic drugs can be selected for use, so cause curing the symptoms, not the disease, and the course of treatment is long take effect slow, even have make the patient that should cure in acute stage, become chronic nephritis because of having delayed best occasion for the treatment.Be prednisone for the main medicine of the nephrotic syndrome in addition, though diuresis is had effect preferably, side effect is bigger, takes for a long time to make patient figure distortion, causes suffering to the patient.
Summary of the invention
The present invention is directed to above-mentioned problems of the prior art, provide a kind of to the acute nephritis instant effect, curative effect is desirable lasting, effective percentage, healing height; The nephrotic syndrome there is better curative effect, and certain cure rate is arranged, have no side effect, treating both the principal and secondary aspects of a disease, short treating period is cured difficult recurrence, the Chinese medicine composition that is used for the treatment of nephritis that cost is low.
The present inventor is a tcm family, research by many decades is because kidney yin is fiery mutually not enough with clinical experience accumulation discovery nephritis pathogenic factor, kidney qi loss, insufficiency of the spleenly can not be good for operation water, and then cause inhibited pulmonary QI to cause that battalion defends imbalance, and cause kidney to be subjected to the pressure of chloride deposition, be difficult to get rid of, lose function once kidney with the passing of time, and even glomerule or renal pelvis develop into inflammation.Tcm diagnosis is debated disease executing and is controlled to debate its disease earlier, and giving consideration to both the incidental and fundamental is a principle.So the traditional Chinese medical science has saying of " medication being as using military forces, and the side of seeing is as seeing rule " to patient treatment, also with regard to saying prudent strictness science remove prescription.
Chinese medicine composition of the present invention contracts, dries and form through the water concentration, and it is to be prepared by weight by following raw materials according:
Phellodendron bark 1-5, CORTEX ACANTHOPANACIS 1-5, Cortex Mori 2-6, Cortex Zingiberis 2-6, Cortex Sclerotii Poriae 2-6, Pericarpium Arecae 1-5, Pericarpium Citri Reticulatae 2-6.
The present invention is prepared by weight by following raw materials according:
Phellodendron bark 3-4, CORTEX ACANTHOPANACIS 3-4, Cortex Mori 3-5, Cortex Zingiberis 4-5, Cortex Sclerotii Poriae 3-5, Pericarpium Arecae 3-4, Pericarpium Citri Reticulatae 4-5.
The present invention is prepared by weight by following raw materials according:
Phellodendron bark 3, CORTEX ACANTHOPANACIS 4, Cortex Mori 5, Cortex Zingiberis 4, Cortex Sclerotii Poriae 3, Pericarpium Arecae 4, Pericarpium Citri Reticulatae 5.
Advantage of the present invention and beneficial effect are as follows:
The present invention is directed to the cause of disease of indication, with the mentioned above principle scientific composition.The phellodendron bark bitter in the mouth is cold, and going into kidney, bladder, large intestine channel is the key medicine of treatment nephritis, biases toward diarrhea Jiao, the kidney invigorating void clearly, system is fire mutually, dysentery bacterium, escherichia coli, streptococcus all there are inhibition and bactericidal action, and platelet is had protection, be difficult for destroyed and the effect of bringing high blood pressure down; CORTEX ACANTHOPANACIS acrid in the mouth, temperature are gone into liver, kidney two warps, and arthritis and analgesic activity are arranged, can enhancing body resistance against diseases, the bone and muscle strengthening network of promoting blood circulation, the deficiency of tonifying liver, kidney.Have peeling edema and rheumatic Bi syndrome down; The Cortex Mori sweet in the mouth, tremble with fear into lung meridian.Lung heat clearing gas, row are strongly fragrant wet, especially can get rid of to accumulate in the more chloride of kidney, and significant diuresis is arranged, and can clearing and antitussive.Have eliminating pathogen from the lung for relieving asthma, retention of water-damp, the full dredging water passages of detumescence; The spleen lung meridian is gone in Cortex Zingiberis acrid in the mouth, cold.The row lung qi is good at the logical epidermis water that looses and is stagnated, and has the hydroderma of disappearing, disperses damp.The Cortex Sclerotii Poriae sweet in the mouth, put down into the lung kidney channel, the hydroderma that disappears, tonneau urine have the hydroderma of offseting specially good effect are arranged; Pericarpium Arecae is gone into spleen, stomach, intestine and small intestine warp, and the intestinal stasis relieving of being good at ventilating, water wet and makes a bet, the inducing diuresis to remove edema effect; Pericarpium Citri Reticulatae is gone into the spleen lung meridian, hot main looses that the family of the victim in a murder case falls, spleen reinforcing is good for the stomach, row lung qi, drying dampness to eliminate phlegm be pleasant active, has the reason lung qi, the effect of strengthening the spleen and stomach, breast association pain due to disorder of QI, dyspepsia distension.Above-mentioned all flavor medicine prescriptions have synergistic function.
The present invention compared with prior art owing to the prescription science proves to the ill and through clinical trial to the acute and chronic nephritis instant effect, cures and does not recur in 2-3 week, and effective percentage reaches 100%, and cure rate reaches more than 90%, has no side effect, and cost is low, alleviates patient economy burden; To nephrotic syndrome determined curative effect, and certain cure rate is arranged.The present invention if can be applied, and it is painful that extensive patients is broken away from, and gets well, and has obvious social.
The specific embodiment
Content of the present invention is described in detail by embodiment, but not limit by embodiment.
Embodiment 1
Get the Cortex Mori of the phellodendron bark of 3 parts of weight, 4 parts of weight CORTEX ACANTHOPANACIS, 5 parts of weight, 4 parts of weight Cortex Zingiberiss, 3 parts of weight Cortex Sclerotii Poriae, 4 parts of weight Pericarpium Arecae and 5 parts of weight Pericarpium Citri Reticulataes and go into extraction vessel together, the water logging bubble that adds three times of dried medicine weight after 2 hours very hot oven got decocting liquid in slow fire boiling 1-1.5 hour after open; Add water again and repeat to extract and once remove slag, twice medicinal liquid mixes, concentrates, oven dry, sterilization, dress 0.25g/ capsule.
Embodiment 2
Get 1 part of weight phellodendron bark, 5 parts of weight CORTEX ACANTHOPANACIS, 2 parts of weight Cortex Mori, 6 parts of weight Cortex Zingiberiss, 5 parts of weight Cortex Sclerotii Poriae, 2 parts of weight Pericarpium Arecae and 6 parts of weight Pericarpium Citri Reticulataes and go into the drying baker oven dry together, be ground into fine powder dress 20g/ bag granule or powder preparation to be taken after being infused in boiling water.
Embodiment 3
Get the Cortex Mori of the phellodendron bark of 5 parts of weight, 2 parts of weight CORTEX ACANTHOPANACIS, 4 parts of weight, 2 parts of weight Cortex Zingiberiss, 2 parts of weight Cortex Sclerotii Poriae, 5 parts of weight Pericarpium Arecae and 2 parts of weight Pericarpium Citri Reticulataes by the method for embodiment 1 extract, concentrate, oven dry adds medically acceptable adjuvant and can be made into various dosage forms such as tablet, ball, cream, oral liquid and all can.
Application Example 1, honest and clean X woman 10 years old, Signs is checked T37.4 ℃, P86 time/minute, BP110/80mmHg, and the puffiness of the eyes obviously, pharyngeal hyperemia, tonsil be that II ° of enlargement, two lung auscultation are the ring sound, the percussion of kidney district is painful, and check urine protein (++ ++), RBC expire the visual field and a plurality of hyaline casts are arranged.Be diagnosed as acute glomerulonephritis, take medicine 0.25g/ capsule of the present invention, each 8 day obeys 3 times, take medicine two weeks check urine protein (-), RBC1-3, and the clinical manifestation waist is painful, edema disappears, and appetite increases, does not have discomfort table disease, follows up a case by regular visits to and does not have recurrence in 1 year.
Example 2, white XX man 39 years old, acute nephritis Signs T36 ℃, P66 time/minute, BP160/110mmHg, painful disease holds that complexion is gloomy, digital marking (+) before the puffiness of the eyes, pharyngeal hyperemia, normal, the two lower limb shin of cardiopulmonary auscultation, check urine protein (++ ++), RBC20-30/HP, granular cast 2-3.With capsule 0.25g of the present invention * 8/time, day clothes 3 times, 1 of two weeks check urine protein (+), cast, edema disappears, and waist is painful, obeys to be almost recovered in a week again, and following up a case by regular visits in 1 year does not have recurrence.
Example 3, all XX man 43 years old, the chronic nephritis course of disease is long, once went Shen medical university Nephrology hospitalization one wheat harvesting period not feel any better, quiet some Signs improvement of one week of antibiotic, but lumbago but increases the weight of, by the agency of comes the court to go to a doctor, Signs is checked T37 ℃, P84 time/minute, R20 time/minute, BP160/100mmHg, the puffiness of the eyes, pain in the lumbar region, urine protein (++ ++), RBC cast 2-3/HP, blood urea nitrogen 17.8mmol/L.With medicine 0.25g capsule of the present invention, each 8, day clothes 3 times are taken the back further consultation of 5 weeks, the puffiness of the eyes disappears, lumbago alleviates, appetite is cumulative, urine protein (++), no cast, blood urea nitrogen 7.8mlmol/L, before two shins digital marking is arranged, the basic healing of 7 weeks of taking medicine followed up a case by regular visits to not have for many years to recur still and is still living and in good health.
Example 4, king XX man 39 nephritis, Signs is checked T36 ℃, P84 time/minute, BP140/90mmHg, and pale complexion, the puffiness of the eyes are not moved back, two kidneys district's percussion painful (+), digital marking (+) before two lower limb shins, urine protein (++ ++), hyaline cast 5-8/HP, blood urea nitrogen 13.6mlmol/L.Take medicine of the present invention 3 0.25g/ grain * 8/ every day time, one week the back Signs obviously alleviate, edema disappears, appetite is cumulative, urine protein (++), cast 1-2/HP, blood urea nitrogen 5.8mlmol/L, 3 weeks were almost recovered, and did not see recurrence.
Example 5 garden XX man 70 nephrotic syndromes successively go to go to a doctor to how tame hospital, are once pronounced the powerless funeral affairs of going back to prepare by the well-known large hospital in Shenyang, and family members are the misery anxiety quite, and by the agency of comes the court's one examination, even the mood that can prolong time and also approve.Feel dizzy, general edema, extremity aching and limp unable, do not think appetite, two skin of lower extremity ulcerations infiltration oliguria, T36 ℃, P60 time/minute, BP200/140mmHg, the look complexion is gloomy, body weight 93Kg, and two just can not take care of oneself, the check urine protein (++ ++), RBC cast 30-40/HP, pus skewer pipe 2-3.With medicine 0.25g/ grain of the present invention * 8/ time, every day 3 times, take 3 week the back Signs obviously alleviate, body weight 76Kg, all coldness of the body, edema is arranged; Check urine protein (+++), cast 1-2/HP, blood urea nitrogen 17.2mlmol/L.5 week back blood pressure 160/100mmHg, no edema, slight lumbago; Two just take care of oneself, and urine protein (++), no cast, blood urea nitrogen 8.2mlmol/L were almost recovered after 7 weeks, and the people is also alive, follow up a case by regular visits to and do not have recurrence in 1 year.
By above-mentioned 5 model cases, although be typical case, objectively respond really really, thereby prove that pharmaceutical composition of the present invention is authentic to the satisfied therapeutic effect of the acute and chronic nephritis of indication.Particularly can also cure the nephritis syndrome substantially, can't but be an important breakthrough controlling the nephritis training, still all medicines were can't be obtained in the past for this.
Clinical trial curative effect of medication visual report of the present invention
The patients that 150 examples suffered from acute and chronic nephritis for the curative effect of further examining medicine of the present invention carry out clinical trial, oppose than test under patient's the identical or proximate situation of the state of an illness, the course of disease and doctor's technology, and observing for 4 weeks is a course of treatment.
Curative effect of medication of the present invention is remarkable, and effective percentage, cure rate height, short treating period have no side effect.Its observed result is reported as follows:
One, clinical data:
Clinical verification selects case all to meet every requirement of defined in the checking design, to be in hospital and out-patient's 150 examples, and test group 100 examples wherein, matched group 50 examples.Each organizes sex, and the age sees Table 1, and clinical manifestation sees Table 2.
Each test group sex of table 1, age
| Group | Total routine number | Age | Sex | |||
| ?10-25 | ?26-50 | ?51-75 | The man | The woman | ||
| Test group | 100 | ?30 | ?50 | ?20 | ?85 | ?15 |
| Matched group | 50 | ?15 | ?20 | ?15 | ?38 | ?12 |
| Add up to | 150 | ?45 | ?70 | ?35 | ?123 | ?27 |
Table 2 clinical manifestation
Two, dosage and method
Test group: the each 0.25g/ grain of medicine of the present invention * 8, day 3 times, be 1 course of treatment half an hour all around after meal, medication period is avoided Sal beans, recovers until detumescence.
Matched group: the general therapeutic method, intramuscular injection every day 800,000 unit penicillins divide 2 times, and allergy sufferers was used tetracycline or matchmaker's element instead in 7-10 days; Be equipped with and align oral 2-3mg/Kg/ day of medicine hydrochlorothiazide, divide 2-3 time; Reserpine 1.5-2.0mg/Kg/ day, every day 3 times.Be a course of treatment all around.In the process of test, cut out other medicine.
Three, criterion of therapeutical effect, judgement:
1, criterion of therapeutical effect:
Effectively: the clinical manifestation symptom makes moderate progress
Produce effects: the clinical manifestation symptom is obviously improved, most transference cures or small amount of residual
Invalid: the clinical manifestation doing well,improving is not obvious
Recovery from illness: the clinical manifestation symptom is near complete or complete obiteration.
2, therapeutic outcome is judged:
Efficient statistics and significance be relatively: test group and matched group are than the comparison sheet of the curative effect difference statistical processing methods with the x2 test:
The efficient statistics of table 3
| Group | Total routine number | Cure rate % | Effective percentage % | Invalid | Total effective rate % | |||
| Example | ?％ | Effectively | Produce effects | Example | ?％ | |||
| Test group | 100 | ?90 | ?90 | ?100 | ?98 | ?0 | 100 | |
| Matched group | 50 | ?15 | ?30 | ?40 | ?20 | ?10 | ?20％ | 80 |
Through x
2Check, test group total effective rate 100%, matched group total effective rate are 80% test group and matched group curative effect significant difference.
Table 4 effectively compares the course of treatment
| Group | Total routine number | Effective time | Cure time | ||||||
| 1 week | 2 weeks | 3 weeks | 4 weeks | 1 week | 2 weeks | 3 weeks | 4 weeks | ||
| Test group | 100 | ?80 | ?18 | ?2 | ?70 | ?15 | ?5 | ||
| Matched group | 50 | ?0 | ?14 | ?26 | ?10 | ?5 | |||
The effectively comparative analysis course of treatment: the fast short treating period of test group produce effects, the recovery from illness of 2 weeks reaches 75 people, the longest the 4th all 5 people, and the matched group onset is slow, the course of treatment is long, just begins after 2 weeks to take effect, the 3rd week recovery from illness 10 people, the 4th all 5 people.
From this group clinical statistics, the total effective rate height of medicine of the present invention, the effective percentage 100% in observing time
Cure and reach 90%; And matched group effective percentage in observing time is lower, cure rate 30% aggregate efficiency 80%.Analyzing and processing by statistics: both curative effect rate significant differences, the short treating period of test group, instant effect obviously is better than matched group.
Four, clinical experience
By adopting medicine of the present invention and the comparison of general therapeutic method in the past, because do not find the reference with it of similar Chinese medicine at present as yet, so just contrast with the Therapeutic Method of common hospital.Although comparability is not too strong, also can play the contrast effect.
1, this group clinical case since anxious slow patient have concurrently, and acute more than chronic, thus visible medicine of the present invention, to acute patient's onset piece, the curative effect ideal, special consumer edema is the fastest, and short treating period, for chronic slow relatively, so though still have the effective or produce effects of 10 patients, also recovery from illness.
2, prove further to execute and control that giving consideration to both the incidental and fundamental principle prescription science is suited the medicine to the illness, and just obtains promising result according to differential diagnosis in tcm from efficacy result.
3, owing to the treatment observing time around only having, thus cause some chronic patients to be cured as yet in observing time, as the extended treatment time still has the healing possibility again.The above case that still finds no recurrence more than 2 years that has through return visit of the patient of Zhi Yuing.
Claims (3)
1, the Chinese medicine composition that is used for the treatment of nephritis is carried, concentrates, is dried and form through water, it is characterized in that being prepared by weight by following raw materials according:
Phellodendron bark 1-5, CORTEX ACANTHOPANACIS 1-5, Cortex Mori 2-6, Cortex Zingiberis 2-6, Cortex Sclerotii Poriae 2-6, Pericarpium Arecae 1-5, Pericarpium Citri Reticulatae 2-6.
2, the Chinese medicine composition that is used for the treatment of nephritis according to claim 1 is characterized in that being prepared by weight by following raw materials according:
Phellodendron bark 3-4, CORTEX ACANTHOPANACIS 3-4, Cortex Mori 3-5, Cortex Zingiberis 4-5, Cortex Sclerotii Poriae 3-5, Pericarpium Arecae 3-4, Pericarpium Citri Reticulatae 4-5.
3, the Chinese medicine composition that is used for the treatment of nephritis according to claim 1 is characterized in that being prepared by weight by following raw materials according:
Phellodendron bark 3, CORTEX ACANTHOPANACIS 4, Cortex Mori 5, Cortex Zingiberis 4, Cortex Sclerotii Poriae 3, Pericarpium Arecae 4, Pericarpium Citri Reticulatae 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100121754A CN100546642C (en) | 2007-07-19 | 2007-07-19 | The Chinese medicine composition that is used for the treatment of nephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100121754A CN100546642C (en) | 2007-07-19 | 2007-07-19 | The Chinese medicine composition that is used for the treatment of nephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101095928A true CN101095928A (en) | 2008-01-02 |
| CN100546642C CN100546642C (en) | 2009-10-07 |
Family
ID=39010151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100121754A Expired - Fee Related CN100546642C (en) | 2007-07-19 | 2007-07-19 | The Chinese medicine composition that is used for the treatment of nephritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100546642C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102225167A (en) * | 2011-05-28 | 2011-10-26 | 宫兆荣 | Traditional Chinese medicine composition for treating pediatric acute nephritis and preparation method thereof |
| CN104666603A (en) * | 2013-11-26 | 2015-06-03 | 天津中敖生物科技有限公司 | Traditional Chinese medicine oral liquid for treating dog nephrotic syndrome and preparation method thereof |
| EP2929888B1 (en) * | 2012-12-06 | 2018-10-10 | Korea Food Research Institute | Composition comprising poria cocos wolf bark extract as active ingredient for use in preventing, improving, or treating th2-mediated allergic diseases |
-
2007
- 2007-07-19 CN CNB2007100121754A patent/CN100546642C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102225167A (en) * | 2011-05-28 | 2011-10-26 | 宫兆荣 | Traditional Chinese medicine composition for treating pediatric acute nephritis and preparation method thereof |
| CN102225167B (en) * | 2011-05-28 | 2012-10-31 | 宫兆荣 | Traditional Chinese medicine composition for treating pediatric acute nephritis and preparation method thereof |
| EP2929888B1 (en) * | 2012-12-06 | 2018-10-10 | Korea Food Research Institute | Composition comprising poria cocos wolf bark extract as active ingredient for use in preventing, improving, or treating th2-mediated allergic diseases |
| CN104666603A (en) * | 2013-11-26 | 2015-06-03 | 天津中敖生物科技有限公司 | Traditional Chinese medicine oral liquid for treating dog nephrotic syndrome and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100546642C (en) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102552773B (en) | Drug for treating bronchitis and bronchial asthma of 7-15 year old children | |
| WO2014139255A1 (en) | Pharmaceutical composition for treating cancers and preparation method thereof | |
| CN100546642C (en) | The Chinese medicine composition that is used for the treatment of nephritis | |
| CN103127464B (en) | Chinese medicament for treating gallstones | |
| CN104306793A (en) | Chinese herba preparation for treating lobar pneumonia | |
| CN103800689A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103393909B (en) | Chinese medicinal preparation for treating biliary calculus with cholecystitis | |
| CN102600272A (en) | Traditional Chinese medicine for treatment of orthopedic disease | |
| CN105327171A (en) | Traditional Chinese medicine electuary for treating mastitis and preparing method thereof | |
| CN106822734A (en) | A kind of numbness relieving and pain relieving externally used medicine bag | |
| CN102784369A (en) | Capsule preparation for treating skin rubella | |
| CN108310354A (en) | A kind of Chinese medicine for treating ankylosing spondylitis | |
| CN101590211B (en) | Pure Chinese medicinal oral preparation for treating psoriasis and preparation method thereof | |
| CN106729521A (en) | It is a kind of to treat Chinese medicine preparation of apoplexy and preparation method thereof | |
| CN105194429A (en) | Traditional Chinese medicine for treating bronchial asthma | |
| CN106110047A (en) | A kind of scarlatinous medicine of integrative therapy children's | |
| CN106177561A (en) | One treats phthisical Chinese medicine composition | |
| CN105535799A (en) | Medicine for treating chronic cholecystitis and preparation method | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection | |
| CN105168945A (en) | External ointment for promoting fracture healing and preparation method of external ointment | |
| CN105362548A (en) | Traditional Chinese medicine for treating allergic asthma | |
| CN105079094A (en) | Traditional Chinese medicine composition for treating hemafecia | |
| CN104721386B (en) | A kind of Traditional Chinese medicine external patch and preparation method thereof for treating asthenic cold type cough and asthma | |
| CN104758888A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN103566302A (en) | Traditional Chinese medicine for treating atrophic gastritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091007 Termination date: 20120719 |